Figure 3.
Both AML ontogeny and ELN risk have independent prognostic values. (A) Kaplan-Meier curves of OS divided by AML ontogeny subtypes. (B) Kaplan-Meier curves of OS divided by genomic classes. Both patients with t(6;9) underwent allo-HSCT. (C) AML ontogeny–related risk was evaluated using multivariable Cox-regression models adjusted for age (modeled by cubic spline), initial treatment at diagnosis, allogenic transplant (modeled as a time-dependent variable), and genomic classes. 7 + 3, daunorubicin + cytarabine, including CPX-351. HMA, hypomethylating agents; low DAC, low-dose cytarabine.

Both AML ontogeny and ELN risk have independent prognostic values. (A) Kaplan-Meier curves of OS divided by AML ontogeny subtypes. (B) Kaplan-Meier curves of OS divided by genomic classes. Both patients with t(6;9) underwent allo-HSCT. (C) AML ontogeny–related risk was evaluated using multivariable Cox-regression models adjusted for age (modeled by cubic spline), initial treatment at diagnosis, allogenic transplant (modeled as a time-dependent variable), and genomic classes. 7 + 3, daunorubicin + cytarabine, including CPX-351. HMA, hypomethylating agents; low DAC, low-dose cytarabine.

Close Modal

or Create an Account

Close Modal
Close Modal